Class I Antiarrhythmic Drug Classification
Class I antiarrhythmics are sodium channel blockers subdivided into three distinct groups (IA, IB, IC) based on their kinetics of sodium channel interaction, effects on action potential duration, and QRS prolongation characteristics. 1, 2
Subclass Characteristics and Mechanisms
Class IA Agents
- Mechanism: Moderate sodium channel blockade with intermediate dissociation kinetics; prolong action potential duration and QT interval
- Examples: Quinidine, procainamide, disopyramide 3, 1, 4
- ECG Effects: Prolong both QRS duration AND JT interval, resulting in QTc prolongation 5
- Typical Dosing:
- Procainamide: 20-50 mg/min IV until arrhythmia suppressed, hypotension occurs, QRS widens by 50%, or maximum 17 mg/kg reached; alternatively 100 mg every 5 minutes 6, 1
- Quinidine: 0.75-1.5 g orally in divided doses over 6-12 hours (with rate-slowing drug) 1
- Disopyramide: Dosing varies by formulation 7
Class IB Agents
- Mechanism: Weak sodium channel blockade with rapid dissociation kinetics; shorten or have minimal effect on action potential duration
- Examples: Lidocaine (lignocaine), mexiletine 8, 2, 9
- ECG Effects: Reduce QT interval by shortening JT interval; no effect on QRS duration 5
- Typical Dosing:
Class IC Agents
- Mechanism: Potent sodium channel blockade with slow dissociation kinetics; minimal effect on action potential duration but marked conduction slowing
- Examples: Flecainide, propafenone 7, 3, 1
- ECG Effects: Significantly prolong QRS duration without affecting JT interval; QT prolongation at paced rates due entirely to QRS widening 5
- Typical Dosing:
Critical Safety Considerations
Class IC agents are absolutely contraindicated in patients with structural heart disease, including ischemic heart disease and heart failure. 7, 3, 10, 11 This stems from the CAST study findings showing increased mortality with these agents in post-MI patients with ventricular ectopy 12.
Proarrhythmic Risk Hierarchy
Class IC drugs carry the highest proarrhythmic risk due to their inability to selectively depress ischemic myocardium, making them inherently more dangerous than Class IB compounds 12. Class IA agents carry intermediate risk, primarily through QT prolongation and torsades de pointes 6, 1.
Common Pitfalls to Avoid
- Never use Class IC drugs without concurrent AV nodal blockade when treating atrial arrhythmias—risk of 1:1 atrial flutter conduction with paradoxical ventricular rate acceleration 3, 10
- Class IA drugs have limited appeal due to multidosing regimens, modest efficacy, and adverse/proarrhythmic effects 7, 3
- Avoid all Class I agents in patients with QT prolongation (particularly IA agents) 6
Clinical Application Algorithm
For patients WITHOUT structural heart disease:
- First-line: Class IC agents (flecainide or propafenone) for supraventricular arrhythmias 7, 3
- Must combine with beta-blocker to prevent rapid ventricular response if atrial flutter develops 3
For patients WITH structural heart disease:
- Class IC agents are contraindicated 7, 3, 10
- Class IA agents have limited role; consider only if other options exhausted 4
- Class IB agents (lidocaine) acceptable for acute ventricular arrhythmias, particularly in witnessed cardiac arrest 2
Specific indications where Class I drugs retain utility:
- Lidocaine: Refractory VT/cardiac arrest (especially witnessed) 2
- Mexiletine: Congenital long QT syndrome 2
- Quinidine: Brugada syndrome 2
- Flecainide: Catecholaminergic polymorphic VT 2, 13
The evidence consistently demonstrates that Class IC agents (flecainide, propafenone) are preferred over Class IA drugs for rhythm control in structurally normal hearts due to better efficacy and tolerability profiles 7, 3, while Class IB agents remain primarily acute-use medications with limited chronic indications.